Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012
Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Microscope technique reveals for first time when and where proteins are made
Scientists at Albert Einstein College of Medicine of Yeshiva University and their international collaborators have developed a novel fluorescence microscopy technique that for the first time shows where and when proteins are produced.

UCSF team finds key to making neurons from stem cells
A research team at UC San Francisco has discovered an RNA molecule called Pnky that can be manipulated to increase the production of neurons from neural stem cells.

New MIND diet may significantly protect against Alzheimer's disease
A new diet, appropriately known by the acronym MIND, could significantly lower a person's risk of developing Alzheimer's disease, even if the diet is not meticulously followed, according to a paper published online for subscribers in March in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Johns Hopkins researchers identify 'missing culprit' in heart failure
Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure.

Who will develop memory problems? New tool may help predict
Researchers have developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia.

Are antipsychotic drugs more dangerous to dementia patients than we think?
Drugs aimed at quelling the behavior problems of dementia patients may also hasten their deaths more than previously realized, a new study finds.

Is it dementia, or just normal aging? New tool may help triage
Researchers at Mayo Clinic developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia.

A speech-based system for the early detection of Alzheimer's disease
Alzheimer's disease is the most significant cause of dementia in the elderly: it affects over 35 million people worldwide.

Scientists grow 'mini-lungs' to aid the study of cystic fibrosis
Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.

UTSW neuroscientists identify cell type in the brain that controls body clock circadian rhythms
UT Southwestern Medical Center neuroscientists have identified key cells within the brain that are critical for determining circadian rhythms, the 24-hour processes that control sleep and wake cycles, as well as other important body functions such as hormone production, metabolism, and blood pressure.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)


Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

Caring for a Person with Alzheimer's Disease

Caring for a Person with Alzheimer's Disease
by National Institute on Aging U.S. Department of Health and Human Services (Author)


This comprehensive handbook offers information and advice for at-home caregivers of people with Alzheimer's disease. It addresses all aspects of care, from bathing and eating to visiting the doctor and getting respite care.

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author)


The first edition of Alzheimer's Disease: What if There Was a Cure?, which details Dr. Newport's discovery and use of medium-chain fatty acids (which act like alternative fuel in the Alzheimer's brain), had such a strong reception in 2011 that a second edition is now in demand. In this updated and expanded version, Dr. Newport, a neonatal practitioner, continues the story of her husband Steve's progress and provides the most recent research on the possible connection between Alzheimer's disease and the herpes simplex virus and nitrosamine substances, as well as how infection, inflammation, and genetic makeup may affect an individual's response to fatty acid therapy. Among many other updates, Dr. Newport details the latest clinicaltrials aimed at removing beta-amyloid, which accumulates in...

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author), Cheryl Hirsch (Editor)


Though Dr. Mary T. Newport has provided professional care to newborns since 1983, she's led a double life since 2000 when she became a caregiver at home. That's when her beloved husband, Steve, first showed signs of Alzheimer's disease. After his deterioration accelerated in 2004, Dr. Newport began avidly researching ways to keep him functional for as long as possible. Since she understands medical terminology and scientific methods, she was thrilled to find new research showing that medium- chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease. When she gave Steve about 2 tablespoons of coconut oil (a source of these fats) at breakfast before a memory test that he had previously failed,...

Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies (Frontiers in Neuroscience)

Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies (Frontiers in Neuroscience)
by Renee D. Wegrzyn (Editor), Alan S. Rudolph (Editor)


In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: The basis of AD and the role of Aβ oligomers in development of disease Existing and emerging in vitro biomarker-based methodologies...

The Alzheimer's Prevention & Treatment Diet

The Alzheimer's Prevention & Treatment Diet
by Richard S. Isaacson MD (Author), Christopher N. Ochner PhD (Author)


Alzheimer’s disease (AD) is a type of dementia that can be very hard on both the patient and the caregiver. Currently, five million Americans have been diagnosed with AD--and that number is likely to triple by 2050. While the cause of Alzheimer’s disease is still a mystery, new research has increased our knowledge of certain aspects of the disease. Perhaps most significant, studies show that proper diet may make a real difference, not only in slowing the progression of AD, but also in preventing it. In this groundbreaking book, a notable expert on Alzheimer’s disease has teamed up with a leading researcher of nutrition to create a unique guide to understanding and managing this serious condition. The Alzheimer’s Prevention & Treatment Diet outlines a cutting-edge nutritional...

Anti-Alzheimer's Action Guide: How to Avoid America's Most Dreaded Disease

Anti-Alzheimer's Action Guide: How to Avoid America's Most Dreaded Disease
by Prime Time, LLC


For many, America’s “most dreaded disease” is not cancer or heart disease. It’s Alzheimer’s. And despite running a 40-year war against this ravaging brain destroyer, and spending untold billions in research for drug development, we have absolutely nothing to suggest an effective treatment is “just around the corner.”

Along the way, we’ve learned that the deterioration in our brains that leads to Alzheimer’s probably begins 10-20 years before our brains show any symptoms of the disease, leading many to conclude that early prevention should be a top priority, and should be pursued as rigorously as drug development. Though not as well funded as the biomedical team, prevention advocates have generated an impressive body of scientific literature that leads to...

Going Gentle Into That Good Night: A Practical and Informative Guide For Fulfilling the Circle of Life For Our Loved Ones with Dementias and Alzheimer?s Disease

Going Gentle Into That Good Night: A Practical and Informative Guide For Fulfilling the Circle of Life For Our Loved Ones with Dementias and Alzheimer?s Disease
by Ms. Sandra Ross (Author)


This book is written to give practical and real-world help to those us responsible for the care of loved ones with dementias and Alzheimer's Disease.

It's not like all those other books. Believe me, I found most of them to be a waste of my time because they were not hands-on and accessible and they didn't tell me the stuff I really needed to know and had to learn on my own.

If you want a lot of theory, this is not the book for you. If you want to read one more book that talks about dementias and Alzheimer's Disease from a high-level and clinical standpoint, this book is not for you.

But you want the succinct and practical experience and advice from somebody who's walked your shoes as when I cared for my mom, this book is for you.

I wish there had been one...

A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier

A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier
by Patricia R. Callone (Author), Connie Kudlacek (Author), Barabara C. Vasiloff (Author), Janaan Manternach (Author), Roger A. Brumback (Author)


An estimated 5 million Americans have Alzheimer's disease. That number continues to grow - by 2050 the number of individuals with Alzheimer's could range from 11.3 million to 16 million. Alzheimer's disease is not a normal part of aging. It is a devastating disorder of the brain's nerve cells that impairs memory, thinking, and behavior. Written for patients, their families, and caregivers, A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier will help readers understand what is physically happening to the brain so they can empower their own special skills and talents throughout the disease process. The book is divided into three sections that correspond to the progression of Alzheimer's and the unique challenges encountered at each stage.Section A: The major part of...

© 2015 BrightSurf.com